Project Description

Author: Selim et al.

Summary:

Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country.

This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at <200 mg/dL for total cholesterol (TC), <150 mg/dL for triglyceride (TG), <100 mg/dL for low-density lipoprotein cholesterol (LDL-C), >40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and <160 mg/dL for non-HDL cholesterol (non-HDL-C).

Result: 3060 patients (age 44.7±13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels <70mg/dL. Only 10.03% achieved the HbA1c target of <7%. 7.4% of patients achieved both HbA1c <7% and LDL <100mg/dL and 5% achieved both HbA1c <7% and LDL <70mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p<0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p<0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p<0.001) were negatively associated with lipid control (LDL <100mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p<0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p<0.001) were positively associated with lipid control.

Conclusion: Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.

Status: Ongoing

Full text link: Not available